ライフサイエンスコーパス: breast implant

1 received either an older or a newer type of breast implant.

2 rtificial cavity related to the capsule of a breast implant.

3 cal symptoms believed to be related to their breast implants.

4 dication for revision in women with silicone breast implants.

5 Over 10 million women worldwide have breast implants.

6 is ongoing regarding the safety of silicone breast implants.

7 ely impacted our perception of the safety of breast implants.

8 nt in samples from women exposed to silicone breast implants.

9 es from women exposed to silicone and saline breast implants.

10 should always use closed systems to inflate breast implants.

11 restricted to studies of silicone-gel-filled breast implants.

12 e-tissue disease that could be attributed to breast implants.

13 occurred years ago in women with and without breast implants.

14 st 5 years before baseline, and did not have breast implants.

15 ures are an important problem for women with breast implants.

16 a, which is associated with textured surface breast implants.

17 the long-term health consequences of having breast implants.

18 ion women in the United States have silicone breast implants.

19 connective-tissue diseases among women with breast implants.

20 nated by studies on the role of silicone gel breast implants.

21 isks of connective-tissue diseases following breast implants.

22 ear trends in RR with increasing duration of breast implants.

23 seem to be increased in women with silicone breast implants.

24 In the prospective cohort, 739 cosmetic breast implants (1.6%) were revised after a median (IQR)

25 1.8 (0.9-3.1) years, and 697 reconstructive breast implants (11.8%) were revised after a median (IQR

26 , 50.6 [12.7] years) and 2945 reconstructive breast implants (2139 women, mean [SD] age, 57.9 [11.3]

27 in the legacy cohort and all 47 564 cosmetic breast implants (24 120 women, mean [SD] age, 32.3 [9.7]

28 e, 32.3 [9.7] years) and 5928 reconstructive breast implants (4688 women, mean [SD] age, 50.9 [11.5]

29 All 12 882 cosmetic breast implants (6667 women; mean [SD] age, 50.6 [12.7]

30 who currently have or are seeking to obtain breast implants about the overall risk of these devices.

31 ely followed women with cytologically proven breast implant ALCL from 2014 to 2019.

32 clinical course, treatment, and outcomes in breast implant ALCL patients.

33 Robust participation in the breast implant ALCL PROFILE registry will improve our kn

34 ective and growing database of patients with breast implant ALCL will further improve our understandi

35 t-associated anaplastic large cell lymphoma (breast implant ALCL) is an uncommon T cell lymphoma, whi

36 have begun to outline the clinical course of breast implant ALCL.

37 ified 52 women with pathologically confirmed breast implant ALCL.

38 The breast implant and the implant pocket were irrigated wit

39 A total of 10,830 women reported breast implants and 11,805 reported connective-tissue di

40 46 women who received cohesive silicone gel breast implants and 343 women who received either an old

41 960-1996), 351 (4.8%) of 7,234 patients with breast implants and 62 (2.9%) of 2,138 patients who had

42 ufficient to rule out an association between breast implants and connective tissue disease-like syndr

43 ot confirmed an association between silicone breast implants and connective tissue diseases, a conclu

44 Evidence on breast implants and other outcomes either was limited or

45 the unexpected relationship between cosmetic breast implants and suicide that has been found in six e

46 The postulated relation between silicone breast implants and the risk of connective-tissue and au

47 main uncommon complications associated with breast implants and to describe and illustrate their fin

48 ion of the bacterial microbiota of the skin, breast, implant and capsule between patients with no cle

49 From a public health perspective, breast implants appear to have a minimal effect on the n

50 Breast implants are associated with well-known common co

51 Most patients with breast implant-associated ALCL who had disease confined

52 ive, and ALK-negative, primary cutaneous and breast implant-associated ALCL.

53 estimate the incidence and incidence rate of breast implant-associated anaplastic large cell lymphoma

54 Breast implant-associated anaplastic large cell lymphoma

55 Though rare, breast implant-associated anaplastic large cell lymphoma

56 Breast implant-associated anaplastic large cell lymphoma

57 Breast implant-associated anaplastic large cell lymphoma

58 The oncogenic events involved in breast implant-associated anaplastic large cell lymphoma

59 Breast implant-associated anaplastic large cell lymphoma

60 Breast implant-associated anaplastic large-cell lymphoma

61 Breast implant-associated anaplastic large-cell lymphoma

62 oid tumors associated with the implants; and breast implant-associated large cell anaplastic lymphoma

63 lly true of late seroma and the diagnosis of breast implant-associated large cell anaplastic lymphoma

64 omas (SBLs), and related subtypes, including breast implant-associated lymphomas (BIA-ALCL) and intra

65 Breast implant-associated lymphomas (BIA-ALCL) constitut

66 Breast-implant-associated anaplastic large-cell lymphoma

67 sted County, Minnesota, and received a first breast implant at the Mayo Clinic between 1964 and 1991.

68 In this cohort study of women with silicone breast implants, BII was an uncommon indication for revi

69 l lymphoma is a rare cancer in patients with breast implants but is increasing in incidence.

70 has greatly increased in women with silicone breast implants, but no studies have ruled out a moderat

71 also show that the surface surrounding human breast implants collected during revision surgeries also

72 imates for any definite CTD among women with breast implants compared with women without breast impla

73 idence that the urine of women with silicone breast implants contain 60 to over 1700 times more plati

74 f female CD-1 mice were injected with either breast implant distillate composed primarily of hexameth

75 The authors identified 220 women with breast implants (exposed) who self-reported CTD and a ra

76 Saline breast implant fluid (n = 2) did not contain detectable

77 Despite the number of patients with breast implants followed by United States Food and Drug

78 ho underwent removal or revision of silicone breast implants from January 1, 1986, to August 18, 2020

79 Pt in explanted silicone breast implant gel (n = 9) occurred mainly in the +2, +4

80 increasingly growing number of patients with breast implants has led to the increased likelihood of c

81 30+ T-cell lymphoma associated with textured breast implants, has adversely impacted our perception o

82 However, textured breast implants have been associated with immune-related

83 Silicone breast implants have been on the market for breast augme

84 Silicone-gel-filled breast implants have been widely used for breast augment

85 date, to show that women exposed to silicone breast implants have Pt levels that exceed that of the g

86 the liver of women with silicone gel-filled breast implants helped measure silicone exposure.

87 Breast implant illness (BII) is a poorly understood dise

88 It is unknown how often breast implant illness (BII) is the indication for revis

89 immunological complications associated with breast implant illness (BII).

90 y lead to medical complications, also called breast implant illness.

91 terventional breast imaging unit to evaluate breast implants in 205 patients between January 2015 and

92 re was no evidence of an association between breast implants in general, or silicone-gel-filled breas

93 The risk of having breast implants in those patients with early symptoms of

94 Interestingly, there are joint and breast implant infections caused by Brucella spp.

95 suicide rate of women who received cosmetic breast implants is approximately twice the expected rate

96 hypothesis that the presence of bacteria on breast implants is associated with capsular contracture.

97 Antibiotic irrigation of breast implants is widely used internationally, but no c

98 phoma (ALCL), a complication associated with breast implants, is rapidly rising in the US.

99 Among a total of 389 women with silicone breast implants (mean [SD] age, 50.5 [11.2] years), 384

100 mples (n = 6) from women exposed to silicone breast implants occurred mainly in the +2 and +4 oxidati

101 sediment was noted in saline-filled silicone breast implants of women who had undergone revision surg

102 ndrome (TOS) secondary to sports activities, breast implants, or median sternotomy.

103 cooking oils, L-tryptophan, silica, silicone breast implants, organic solvents, and other agents such

104 This is the largest study of breast implant outcomes.

105 acokinetics of antibiotic prophylaxis in the breast implant pocket.

106 that the platinum used in the manufacture of breast implants (Pt0) is converted by a unknown process

107 ve, and phrenic nerve stimulators as well as breast implant radiofrequency markers.

108 antibodies was found in symptomatic silicone breast implant recipients who often have fibromyalgia.

109 ntration of silicon in the blood of silicone breast implant recipients, as determined by ICP analysis

110 Data were obtained from the Dutch Breast Implant Registry.

111 lective participation by affected women with breast implants remains a plausible alternative explanat

112 derlying cause, and patients often resort to breast implant removal and capsulectomy to alleviate sym

113 y studied consecutive patients who underwent breast implant removal for reasons other than overt infe

114 , AND PARTICIPANTS: A legacy cohort study on breast implant revision surgery was conducted between Ap

115 Breast implant revision with the indication BII or local

116 mplications are a far more common reason for breast implant revision.

117 metic revisions (4.2%) and 80 reconstructive breast implant revisions (2.7%) were performed because o

118 r after placement of silicone gel-containing breast implants (SBI).

119 en with noncohesive or cohesive silicone gel breast implants, silicone leakage occurred in 98.8% of w

120 implants in general, or silicone-gel-filled breast implants specifically, and any of the individual

121 nces we found between women with and without breast implants suggest that consideration and evaluatio

122 stress injury, the side effects of silicone breast implants, the Gulf War syndrome, chronic whiplash

123 Compared with women who did not report breast implants, the relative risk (RR) of the combined

124 icians involved in the care of patients with breast implants to be aware of this entity and be able t

125 for future diagnostic assays for women with breast implants to distinguish seroma caused by BIA-ALCL

126 nd Drug Administration changed the status of breast implants to investigational.

127 CTD and a random sample of 879 women without breast implants (unexposed) who also self-reported CTD,

128 differences and continue to monitor textured breast implant utilization.

129 ected suicide rate among women with cosmetic breast implants warrants further research.

130 tive-tissue disease among those who reported breast implants was 1.24 (95% confidence interval, 1.08

131 ed that the rate of suicide among women with breast implants was greater than that of women who under

132 The odds ratio for exposure to breast implants was increased, but not significantly (OR

133 on in samples from women exposed to silicone breast implants were as follows: whole blood, 568.1 +/-

134 There was no evidence that breast implants were associated with a significant incre

135 Women with breast implants were more likely to drink a greater aver

136 Removed breast implants were processed using a vortexing/sonicat

137 Silicone gel breast implants were removed from the U.S. market for co

138 female health professionals with and without breast implants who reported CTD on mailed questionnaire

139 g BREAST-AB trial (Prophylactic Treatment of Breast Implants With a Solution of Gentamicin, Vancomyci

140 niaturized or full-scale clinically approved breast implants with different surface topography (avera

141 breast implants compared with women without breast implants would be similar in analyses of self-rep

142 nusual Brucella strain (BO1) isolated from a breast implant wound in a 71-year-old woman with clinica